મુખ્ય પાનુંકંપનીઓવિશ્લેષણલૉગિન
Back to IPO calendar
PricedNASDAQ: BKHAIndustry: Biological Products, (No Diagnostic Substances)Blank-check company (SPAC)
Read the prospectus
B

Vesicor Therapeutics IPO

Vesicor Therapeutics Holdings, Inc. · Danville, CA

IPO price

—

Listed

Mar 22, 2024

975 days ago

Raised

—

Registered maximum

Black Hawk is a blank-check company raising cash to merge with one private business in any industry or region.|Read more

Key takeaways

Summarised with AI from the 424B4 filed Mar 22, 2024. Check the prospectus before relying on it.

  1. 1Black Hawk raised $69.0 million by selling 6,900,000 units at $10.00, and $69,345,000 ($10.05 per public share) is placed in trust.
  2. 2Black Hawk has 15 months to close a merger, extendable twice by three months up to 21 months; each extension requires the sponsor to deposit $690,000 into the trust.
  3. 3The sponsor paid $25,000 for its founder shares, about $0.0145 per share, and will own about 21.96% of the shares after the offering.
  4. 4The auditor raised substantial doubt about Black Hawk's ability to continue as a going concern; it had $125,100 in cash and a $100,853 working capital deficit at November 30, 2023.
  5. 5Units carry rights rather than warrants: each right converts into one-fifth of a Class A share when a merger closes, and the rights expire worthless if no merger is completed.

Going-concern warning: may not have enough money to operate for the next year without new funding

Dual-class shares: some shares carry more votes than the ones sold in the IPO

Emerging growth company · Smaller reporting company

Offering terms

Units on the Nasdaq Global Market

Shares offered
6.90M
Over-allotment
1.03M
Net proceeds (est.)
$0
Underwriting discount
4.5%
Offering expenses
$875K
Lock-up
150 daysEnds ~Aug 19, 2024
Who is locked up
Sponsor and initial shareholders (founder shares); sponsor (private units); EF Hutton (representative shares). Founder shares are released at the earlier of six months after the merger or once Class A shares close at or above $12.00 on 20 of 30 trading days after the merger. Private units are locked until 30 days after the merger. Representative shares are locked until the later of the merger or 180 days.
Dividends
Black Hawk has not paid cash dividends and does not plan to pay any before completing its merger.

About Vesicor Therapeutics

Black Hawk Acquisition Corporation is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on September 28, 2023. It has no operations or revenue. Its only purpose is to find and merge with one or more operating businesses.

Black Hawk sold 6,900,000 units at $10.00 each. Each unit holds one Class A share and one-fifth of a right. Each whole right converts into one Class A share when a merger closes. About $69.35 million ($10.05 per public share) goes into a U.S. trust account. Shareholders can redeem their shares for their portion of the trust if they don't want to take part in a deal.

Black Hawk has 15 months to complete a merger, which it can extend twice by three months each, up to 21 months. It does not limit its search to any industry or region. It says it is looking at targets with an enterprise value of about $180 million to $1 billion. The company is run by Kent Louis Kaufman, who is Chairman, CEO and CFO, and it has no specific target yet.

Stage
Blank-check company (SPAC)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Danville, CA
CEO
Kent Louis Kaufman
Founded
2023
Fiscal year end
Nov 30
SEC CIK
2000775

SPAC terms

A blank-check company raises cash first, then looks for a private company to merge with.

Each unit
One Class A ordinary share and one-fifth of one right
In trust per unit
$10.05
Trust account
$69.3M
Time to find a deal
15 monthsOr the trust is returned
Sponsor
Black Hawk Management LLC
Target focus
Any industry or region; enterprise value of about $180 million to $1 billion
Sponsor stake
Approximately 20% of outstanding shares after the offering (excluding representative shares and private placement shares)

Strategy

Black Hawk has no business of its own and earns no revenue. It plans to use the trust money to merge with an operating company, and until then its only income is interest on the trust.

Market opportunity

Black Hawk does not limit its search to any industry or region. It plans to look for targets with an enterprise value of about $180 million to $1 billion in large markets with room to grow.

Strengths, as the company sees them

  • Management network across several industries and global markets
  • Experience structuring and executing deals
  • Experience with cross-border transactions

Strategy

  • Target companies with an enterprise value of about $180 million to $1 billion
  • Look for strong, experienced management teams
  • Favor targets with defensible market positions, IP, technology or brand
  • No restriction on target geography
  • Acquire businesses that would benefit from a U.S. public listing

Financials (USD)

Black Hawk is a new shell company with no revenue, $125,100 in cash, a $250,000 sponsor loan and going-concern doubt before the IPO.

Balance sheet, Nov 30, 2023

Cash & investments
$125K
Debt
$250K
Stockholders' equity
$6K

Key metrics

Amount placed in trust
$69,345,000At IPO closing
Trust value per public share
$10.05At IPO closing
Working capital deficit
$100,853As of November 30, 2023
Expected annual trust interest (at 4.50%)
$3,120,525Post-IPO estimate
Cash held outside trust
$445,000At IPO closing

Use of proceeds

Nearly all of the money, $69,345,000, goes into a trust account to fund a merger or repay shareholders who redeem. Black Hawk keeps $445,000 outside the trust to pay for its search for a target.

Net proceeds to the company
$69.8MAt $10.00 per unit, no over-allotment
Cash expected to last
At least 15 monthsWith existing cash
  1. 1
    Deposited in trust account for the business combination or shareholder redemptions$69.3M
  2. 2
    Legal, accounting and third-party expenses for target search, due diligence and deal negotiation$140K
  3. 3
    Legal and accounting fees for SEC reporting$50K
  4. 4
    Due diligence and research on prospective targets, including management expense reimbursement$50K
  5. 5
    Administrative fee to the sponsor ($10,000 per month for 15 months)$150K
  6. 6
    Working capital and reserves$55K

Ownership & dilution

Shares before IPO
1.98M
Shares after IPO
8.92M
Insiders own after IPO
22%
Dilution to new buyers
$8.93/share107% of the price
Book value per share after
$-0.60vs $8.33 paid
Selling stockholders
None

Class B founder shares convert one-for-one into Class A shares when a merger closes, and 258,750 Class B shares are forfeited if the over-allotment option is not exercised.

Principal holdersBeforeAfter
Black Hawk Management LLC (Sponsor) · Sponsor100%22%
Kent Louis Kaufman · Insider100%22%

Management & board

NameBackground
Executive officers
Kent Louis Kaufman, 66Chairman, Chief Executive Officer, Chief Financial Officer and DirectorCEO of Growth and Leadership Center since 2004; managing partner at BEEC Capital; consultant for Korn Ferry; earlier at StorMedia and IBM
Board of directors
Brandon Miller, 61Independent Director NomineeManaging partner of Aspect Property Management; director of Yotta and Quetta Acquisition Corporations
Daniel M. McCabe, 74Independent Director NomineeRuns Daniel McCabe LLC law practice; director of Yotta and Quetta Acquisition Corporations
Terry W. Protto, 75Independent Director NomineeFormer Macy's Vice Chairman-Operations and Finance; former CEO/President of Alpine 4 Holdings

Funding before the IPO

Private rounds and loans disclosed in the registration statement.

DateRoundAmountPrice/share
Oct 16, 2023Founder sharesBlack Hawk Management LLC$25K$0.0145
Oct 16, 2023Sponsor promissory noteBlack Hawk Management LLC$250K—
Mar 2024Private placement unitsBlack Hawk Management LLC$2.4M$10

Key risks

The most important of the risk factors the company lists. The prospectus has the full list.

  1. 1
    No target and a fixed deadline

    Black Hawk has no merger target and must close a deal within 15 months, or up to 21 months with paid extensions. If it fails, public shares are redeemed from the trust and the rights expire worthless.

  2. 2
    Going concern doubt

    The auditor raised substantial doubt about Black Hawk's ability to continue as a going concern. At November 30, 2023, it had $125,100 in cash and a $100,853 working capital deficit.

  3. 3
    Heavy dilution

    New investors face immediate dilution of $8.93 per share, or 107.2%, after counting the shares issued for the rights. Founder shares cost the sponsor about $0.0145 each.

  4. 4
    Conflicts of interest

    Two independent directors also sit on the boards of Yotta and Quetta Acquisition Corporations and may have to offer deals to those companies first. Management does not work full-time on Black Hawk's affairs.

  5. 5
    Limited SPAC experience

    Black Hawk's officers and directors have no prior experience completing a merger for a blank-check company.

  6. 6
    Limited voting rights for public holders

    Before a merger, only Class B holders, which means the sponsor, can vote on appointing or removing directors. The sponsor has agreed to vote its shares in favor of the merger.

  7. 7
    Trust exposed to creditor claims

    Creditors' claims on the trust account could take priority over public shareholders. That could reduce the amount paid out per share.

Underwriters & advisers

Bookrunners
EF Hutton LLC
Co-managers
B. Riley Securities, Inc., RF Lafferty & Co., Inc.
Auditor
MaloneBailey, LLP
Company counsel
Celine and Partners, P.L.L.C.; Ogier (Cayman Islands)
Underwriters' counsel
Robinson & Cole LLP
Transfer agent
Continental Stock Transfer & Trust Company, 1 State Street, New York, New York 10004
Over-allotment window
45 days

Prospectus & SEC filings

The registration statement, its amendments and the final prospectus, straight from SEC EDGAR.

DateFormDocumentOpen
Nov 20, 202625-NSE25-NSE
Nov 20, 2026CERTExchange listing certification
Nov 20, 20268-A12BExchange registration (8-A)
Mar 22, 2024424B4Final prospectus (424B4)
Mar 21, 2024CERTExchange listing certification
Mar 20, 2024EFFECTSEC notice of effectiveness
Mar 20, 20248-A12BExchange registration (8-A)
Mar 8, 2024S-1/AAmended registration (S-1/A) · 2 documents
Feb 26, 2024S-1/AAmended registration (S-1/A) · 5 documents
Feb 5, 2024S-1Registration statement (S-1) · 22 documents
Dec 21, 2023DRSConfidential draft (DRS) · 2 documents

Vesicor Therapeutics IPO: frequently asked questions

Vesicor Therapeutics priced its IPO on Mar 21, 2024 and began trading on the Nasdaq Global Market under the ticker BKHA on Mar 22, 2024.

More IPOs

Upcoming and recently priced deals.

Source: Vesicor Therapeutics Holdings, Inc.'s filings on SEC EDGAR. Dates marked approximate are derived from filing dates. Summaries are AI-assisted; the prospectus is the authority. This page is for information only and is not investment advice.